^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Clear Cell Renal Cell Carcinoma
    Drug Class:Immunotherapy +
    Tyrosine kinase inhibitor
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    ASCO.org
    Title:

    Management of Metastatic Clear Cell Renal Cell Carcinoma: ASCO Guideline

    Published date:
    06/21/2022
    Excerpt:
    Patients with metastatic ccRCC with sarcomatoid features should receive ICI-based combination first-line treatment (ipilimumab plus nivolumab, or alternatively, an ICI plus a TKI...
    DOI:
    10.1200/JCO.22.00868